Memo Therapeutics
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 27, Schlieren, Zurich, 8952,...Phone Number
+41 445159140Website
www.memo-therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Memo Therapeutics
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The companys antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties. Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species andRead more
Memo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Memo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Memo Therapeutics recently announced quarterly report
Product Launch: Get notified when Memo Therapeutics launches new products
Check out if Memo Therapeutics is spiking on competitors!
Click to see if Memo Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Memo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Memo Therapeutics
Funding: Get notified immidiatlly once Memo Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if Memo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Memo Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Memo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Memo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Memo Therapeutics.
Memo Therapeutics financials insights
Gather financial insights about Memo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$2.4M
2022
Series B
$40M
2024
Series C
$49.6M
Memo Therapeutics Tech Stack
A closer look at the technologies used by Memo Therapeutics
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Memo Therapeutics News & Media
Ipsen bolsters rare disease pipeline in €700m Memo takeover
This is Ipsen’s second acquisition this week, following its blockbuster Kartos buyout on 29 June.Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus (BKPyV). BK polyomavirus associated nephropathy (BKPyVAN) is a serious andMemo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026
Schlieren / Zurich, Switzerland, 18 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces the presentation of data from its Phase II clinical trial of potravitug at the American Transplant Congress (ATC) 2026, taking place from 20-24 June in Boston, USA.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Memo Therapeutics
Sign Up For FreeTo access detailed company insights
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The companys antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensiti... Read More
